| Company Name: | Abbott Laboratories | | Ticker Symbol: | ABT | | | WWW Address: | www.abbott.com |
| CEO: | Miles D. White | | No. of Employees: | 91,000 |
| Common Issue Type: | CS | | Business Description: | Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a broad and a line of health care products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 36.59 |  -0.24 | - | - | 36.82 | 36.94 | 36.29 | 7050721 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 57,038.9 | 1,558.9 | 0.38 | 3.72 | 2.01 | 11.1 | 1.5 | 37.70 - 28.45 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 36.59 | $ | | PE Ratio - LTM | 11.1 | |
| Market Capitalisation | 57,038.9 | mil |
| Latest Shares Outstanding | 1,558.9 | mil |
| Earnings pS (EPS) | 3.72 | $ |
| Dividend pS (DPS) | 2.01 | ¢ |
| Dividend Yield | 1.5 | % |
| Dividend Payout Ratio | 54 | % |
| Revenue per Employee | 438,175 | $ |
| Effective Tax Rate | 4.8 | % |
| Float | 1,532.1 | mil |
| Float as % of Shares Outstanding | 97.5 | % |
| Foreign Sales | 23,090 | mil |
| Domestic Sales | 16,784 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 10.20 | % |
| Gross Profit Margin | 67.7 | % |
| EBITDA Margin | 27.2 | % |
| Pre-Tax Profit Margin | 14.8 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 15.2 | % |
| Return on Equity (ROE) | 28.8 | % |
| Return on Capital Invested (ROCI) | 25.0 | % |
| Current Ratio | 1.8 | |
| Leverage Ratio (Assets/Equity) | 1.9 | |
| Interest Cover | 13.9 | |
| Total Debt/Equity (Gearing Ratio) | 0.31 | |
| LT Debt/Total Capital | 13.0 | % |
| Working Capital pS | 5.57 | $ |
| Cash pS | 2.81 | $ |
| Book-Value pS | 14.49 | $ |
| Tangible Book-Value pS | 4.56 | $ |
| Cash Flow pS | 5.75 | $ |
| Free Cash Flow pS | 1.75 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.53 | |
| Price/Tangible Book Ratio | 8.03 | |
| Price/Cash Flow | 6.4 | |
| Price/Free Cash Flow | 20.9 | |
| P/E as % of Industry Group | 53.0 | % |
| P/E as % of Sector Segment | 41.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 02/14/2013 |
| Dividend Ex-Date | 04/10/2013 |
| Dividend Record Date | 04/14/2013 |
| Dividend Pay Date | 05/14/2013 |
| Dividend Amount | 140 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.56 |
| Current Dividend Yield | 1.5 |
| 5-Y Average Dividend Yield | 6.6 |
| Payout Ratio | 54.0 |
| 5-Y Average Payout Ratio | 52.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.2 | 99 | 68,745 | 334,943 |
| 4 Weeks | 37.70 | 35.58 | 37.20 | -1.6 | 92 | 60,423 | 1,208,466 |
| 13 Weeks | 37.70 | 33.27 | 35.08 | 4.3 | 95 | 73,319 | 4,619,128 |
| 26 Weeks | 37.70 | 29.96 | 30.09 | 21.6 | 99 | 106,131 | 13,160,269 |
| 52 Weeks | 37.70 | 28.45 | 29.46 | 24.2 | 97 | 123,505 | 30,752,828 |
| YTD | 37.70 | 31.64 | - | 16.8 | 100 | 96,016 | 9,121,496 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 36.90 | 36.50 | 35.97 | 33.62 | 33.26 | 0.38 | 0.53 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 7.77 | 89.0 | 5.84 |
| Income | 4.08 | 28.4 | 2.89 |
| Dividend | 8.05 | 86.4 | 5.27 |
| Capital Spending | 15.81 | NA | -17.96 |
| R&D | 11.86 | NA | 9.90 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -43.1 | -43.1 | 2.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | -56.4 | -56.4 | 23.6 |
| EPS $ | -0.44 | -0.44 | 0.71 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 26.83 |
| Current Ratio | 2.4 |
| Quick Ratio (Acid Test) | 1.7 |
| Liquidity Ratio (Cash) | 1.14 |
| Receivables Turnover | 5.2 |
| Average Collection Period | 69 |
| Working Capital/Equity | 67.5 |
| Working Capital pS | 11.44 |
| Cash-Flow pS | 5.55 |
| Free Cash-Flow pS | 1.97 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.29 |
| Financial Leverage Ratio (Assets/Equity) | 2.5 |
| Debt Ratio | 60.3 |
| Total Debt/Equity (Gearing Ratio) | 0.77 |
| LT Debt/Equity | 0.68 |
| LT Debt/Capital Invested | 60.8 |
| LT Debt/Total Liabilities | 44.6 |
| Interest Cover | 11.6 |
| Interest/Capital Invested | 1.10 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 11.43 |
| Tobin's Q Ratio | 0.85 |
| Current P/E Ratio - LTM | 11.10 |
| Enterprise Value (EV)/EBITDA | 7.38 |
| Enterprise Value (EV)/Free Cash Flow | 26.29 |
| Dividend Yield | 1.5 |
| Price/Tangible Book Ratio - LTM | 8.03 |
| Price/Book Ratio - LTM | 2.53 |
| Price/Cash Flow Ratio | 6.4 |
| Price/Free Cash Flow Ratio - LTM | 20.9 |
| Price/Sales Ratio | 1.59 |
| P/E Ratio (1 month ago) - LTM | 11.3 |
| P/E Ratio (26 weeks ago) - LTM | 7.3 |
| P/E Ratio (52 weeks ago) - LTM | 9.1 |
| 5-Y High P/E Ratio | 9.4 |
| 5-Y Low P/E Ratio | 5.4 |
| 5-Y Average P/E Ratio | 8.1 |
| Current P/E Ratio as % of 5-Y Average P/E | 138 |
| P/E as % of Industry Group | 53.0 |
| P/E as % of Sector Segment | 41.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 10.9 |
| PER SHARE FIGURES |
| LT Debt pS | 11.47 |
| Current Liabilities pS | 8.42 |
| Tangible Book Value pS - LTM | 4.56 |
| Book Value pS - LTM | 14.49 |
| Capital Invested pS | 28.74 |
| Cash pS - LTM | 2.81 |
| Cash Flow pS - LTM | 5.75 |
| Free Cash Flow pS - LTM | 1.75 |
| Earnings pS (EPS) | 3.72 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 7.80 |
| Free Cash Flow Margin 5YEAR AVG | 4.43 |
| Net Profit Margin | 15.0 |
| Net Profit Margin - 5YEAR AVRG. | 12.2 |
| Equity Productivity | 1.49 |
| Return on Equity (ROE) | 22.3 |
| Return on Equity (ROE) - 5YEAR AVRG. | 18.6 |
| Capital Invested Productivity | 0.89 |
| Return on Capital Invested (ROCI) | 13.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 12.0 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 8.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | 7.5 |
| Gross Profit Margin | 67.7 |
| Gross Profit Margin - 5YEAR AVRG. | 66.3 |
| EBITDA Margin - LTM | 27.2 |
| EBIT Margin - LTM | 16.2 |
| Pre-Tax Profit Margin | 15.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 17.4 |
| Effective Tax Rate | 4.8 |
| Effective Tax Rate - 5YEAR AVRG. | 14.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 172 |
| Revenue per Employee | 438,175 |
| Net Income per Employee | 65,527 |
| Average Collection Period | 69 |
| Receivables Turnover | 5.2 |
| Day's Inventory Turnover Ratio | 103 |
| Inventory Turnover | 3.5 |
| Inventory/Sales | 9.5 |
| Accounts Payble/Sales | 4.51 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 2.21 |
| Fixed Assets Turnover | 1.11 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 3.69 |
| Revenue per $ Plant | 4.95 |
| Revenue per $ Common Equity | 1.49 |
| Revenue per $ Capital Invested | 0.89 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 29.9 |
| Research & Devlopment (R&D) as % of Revenue | 10.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 10.8 |
|
|  
| | |  |  | |
| |
